Michael Castagna Chief Executive Officer
Michael Castagna became CEO of MannKind Corporation in 2017, bringing over 25 years of experience in healthcare, pharmaceuticals, and biotechnology. Prior to joining MannKind, he served as a Vice President at Amgen, where he guided the Lifecycle Management and Global Commercial Biosimilar business areas. He also spent a combined ten years at Bristol-Myers Squibb, focusing on medical, marketing, and sales, and directed the Immunoscience division. Earlier in his career, he was Vice President and Division Head for Biopharmaceuticals, North America, at Sandoz (Novartis), where he established the U.S. Biologics Business Unit and relaunched Omnitrope. He also held positions at Merck, Serono, Pharmasset, and DuPont Pharmaceuticals.
Christopher Prentiss Chief Financial Officer
Christopher Prentiss was appointed Chief Financial Officer of MannKind, effective April 22, 2024. He brings over two decades of financial leadership experience in the biopharma sector. Most recently, he served as CFO of ADARx Pharmaceuticals, Inc., a privately held clinical-stage biotechnology company, where he helped raise nearly $250 million in funding. From April 2015 to November 2021, he held a series of finance positions at Adamas Pharmaceuticals, Inc., culminating in CFO, and guided the company through a successful acquisition. His responsibilities at Adamas included finance, accounting, investor relations, information technology, and facilities. During his tenure, Adamas launched GOCOVRI® and acquired OSMOLEX® ER. At the time of its acquisition by Supernus Pharmaceuticals, Inc. in 2021, Adamas had an annual revenue run rate of approximately $100 million. Prentiss was first introduced to the biopharmaceutical industry in 2005 when he initially joined MannKind, serving for over six years, including as its Corporate Controller. He also held senior financial roles at InterMune, Inc. and Dynavax Technologies Corporation. He began his career in the assurance practice at KPMG LLP. Prentiss is a licensed CPA (inactive) in California and holds a B.S. in Accounting from Loyola Marymount University and an MBA from Indiana University's Kelley School of Business.
Dominic Marasco President, Endocrine Business Unit
Dominic Marasco joined MannKind as President, Endocrine Business Unit, effective January 6, 2025. He brings over 25 years of experience in driving commercial success in the biopharma and biotech sectors. Prior to MannKind, he was Executive President and Chief Commercial Officer for Envision Pharma Group, leading its technology and artificial intelligence business units. Before that, he served as Chief Commercial Officer at BioAgilytix Labs, Inc. He also held the role of EVP, Global Business Development, Commercial Group at Syneos Health, and various leadership positions at Amgen, Inc., including Head of U.S. Sales for the Neuroscience Business Unit and Global Commercial Head, Amgen Biosimilars. Mr. Marasco also had commercial leadership roles at Sandoz Biopharmaceuticals (a Novartis Company) and Quintiles Transnational Holdings Inc (now IQVIA). He began his career as a pharmacist before joining Eli Lilly and Company in sales.
Ajay Ahuja Executive Vice President and Chief Medical Officer
Dr. Ajay Ahuja was appointed Executive Vice President and Chief Medical Officer of MannKind, effective September 29, 2025. He is a pediatrician and cardiologist with over two decades of biopharmaceutical leadership experience, spanning medical devices, drug delivery platforms, and biopharmaceuticals. His expertise includes therapeutic areas such as diabetes, cardiovascular disease, respiratory medicine, and infectious diseases. Before joining MannKind, Dr. Ahuja was Development and Launch Leader at Kardigan Bio. He also held senior leadership roles at Idorsia Pharmaceuticals, Allergan (as Global Head of Medical Affairs), Takeda Pharmaceuticals (as Global Medical Head for its cardiometabolic franchise), Pfizer, GSK, and Novartis. Dr. Ahuja practiced medicine at Boston Children's Hospital for over a decade. He earned his MD from Washington University and an MBA from Harvard Business School.
Stuart Tross Chief People & Workplace Officer
Stuart Tross serves as MannKind's Chief People & Workplace Officer, a role he has held since 2016, leading human resources activities and supporting the company's culture. He has several decades of leadership experience in the life sciences industry. From 2006 to 2016, he held roles of increasing responsibility at Amgen, including Senior Vice President and Chief Human Resources Officer, responsible for Human Resources and Security globally. Prior to that, from 1998 to 2006, he served in various leadership roles at Bristol-Myers Squibb, with his last three years as Vice President and Global Head of Human Resources for Mead Johnson Company (which was owned by Bristol Myers Squibb at the time). His early career included a management stint at Towers Perrin (now Willis Towers Watson). Stuart received a B.S. degree from Cornell University and M.S. and Ph.D. degrees in Industrial-Organizational Psychology from the Georgia Institute of Technology.
